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Abstract 
Clinical guidelines from around the world recommend the delivery of psychosocial interventions as part of 
routine care in opiate substitution treatment (OST) programmes.  However, although there are numerous 
individual studies demonstrating benefit for structured psychosocial interventions, meta-analytic reviews 
find no benefit for manual-based treatments beyond ‘routine counselling’. The authors consider the 
question of whether OST medication alone is sufficient to produce the required outcomes, or whether 
greater efforts should be made to provide high quality psychosocial treatment alongside medication. In 
doing so they consider the nuances and limitations of the evidence, and conclude by suggesting ways in 
which the research community may try to explore these issues in the future. Steering a path between overly 
optimistic or nihilistic interpretations of the value of psychosocial treatment appears to be the most 
pragmatic approach. 
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What is Being Debated? 
Fifty years since it was first introduced, the evidence base for the efficacy of opiate substitution treatment 
(OST) in reducing illicit opiate-related harms is extensive (1). When OST was first presented as a treatment 
strategy for opiate dependence in the 1960s, the process of prescribing methadone went hand-in-hand with 
efforts at psychosocial rehabilitation. 
“We have in common the goal of enabling previously criminal persons to lead socially acceptable, crime-free 
lives. This will not be done simply by dispensing methadone. If crime is to be reduced significantly, we need 
an effective rehabilitation program” (2) 
A review of OST clinical guidelines from around the world suggests that psychosocial interventions are still a 
crucial part of treatment (3-6). Every guideline mentions of the need for psychosocial treatment or 
counselling, and some devote up to 10% of the document to detailing these interventions. However, RCTs 
have provided evidence for the effectiveness of directly administered methadone without drug abuse 
counselling for one month (7), four months (8), or six months (9), and systematic reviews suggest that 
methadone without counselling is more effective in reducing substance use than being waitlisted for 
treatment or receiving psychosocial treatment with or without placebo (10). Studies of office-based OST 
delivered with minimal or no counselling beyond standard medication management show rates of treatment 
retention and improvement in illicit drug use comparable to OST with counselling (11-13). Some 
commentators have suggested that in contrast to ‘an implicit judgement that medication is only an adjunct 
to the “truly effective components” of counselling and recovery work’, there is an argument that medication 
itself is treatment, and that psychosocial interventions may not be needed at all (at least for some) (14). 
The authors have recently been members of the psychosocial interventions sub-group of the expert 
committee reviewing national guidelines for the treatment of drug misuse in the United Kingdom. The UK is 
committed to evidence-based treatment, and so we consider the debate around the strength of the 
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evidence base to support psychosocial interventions alongside OST, and suggest possible ways of moving 
things forward. 
 
Evidence for psychosocial interventions for drug misuse 
Psychosocial interventions form the mainstay of treatment for (non-opioid) drug dependence. Carroll has 
noted the impressive evidence base emerging for them through increasingly sophisticated clinical trial 
methodology (15), citing systematic review-based evidence for contingency management (16), family 
therapies (17), motivational interviewing (18) and relapse prevention (19). A systematic review and meta-
analysis of psychosocial interventions for all substance use disorders identified 35 treatment trials involving 
2,340 patients (20). Treatments evaluated included contingency management, relapse prevention, general 
cognitive behaviour therapy, and treatments combining cognitive behaviour therapy and contingency 
management. Overall, such treatments provided benefits reflecting a moderate effect size (d=0.45).  
 
Its all down to the medication: The case for therapeutic nihilism 
However, the picture is less clear when the efficacy of additional psychosocial services in OST is considered. 
Amato and colleagues reviewed 13 different treatments in a meta-analysis of 35 studies including 4319 
participants (21). There was no benefit for any psychosocial intervention plus any maintenance 
pharmacological treatment when compared to standard maintenance treatment in terms of retention in 
treatment, opiate abstinence during or after the treatment, compliance, or psychiatric symptoms. The 
authors concluded that adding any psychosocial support to standard maintenance treatment did not add 
additional benefits. A review of a further 22 studies (22) supported the efficacy of providing psychosocial 
interventions in combination with medications to treat opioid addictions, but found that the incremental 
utility varied across studies, outcomes, medications and interventions. More importantly from a UK 
perspective,  a systematic review of the same literature by the National Collaborating Centre for Mental 
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Health only found evidence for contingency management and mutual self-help (23),  concluding that 
cognitive behavioural therapy and psychodynamic therapy focused on the treatment of drug misuse should 
not be offered routinely to people receiving opioid maintenance treatment. This evidence appears to 
contradict the importance attributed to psychosocial interventions in OST clinical guidelines, and 
undermines recent expert group guidance in the UK (24). So why is there a gap between routine practice and 
research evidence? 
 
The complexity of the opiate-using population seeking treatment 
The evidence for treatment of heroin dependence suggests poorer outcomes than for equivalent groups 
with other drug or alcohol problems (25). When the impact of psychosocial treatments is compared, 
interventions for cannabis use produce the greatest effect sizes (d=0.81), followed by cocaine use (d=0.62), 
opiate use (d=0.39) and polysubstance use (d=0.24) (20). People with heroin dependence have a greater 
likelihood of life problems prior to dependence, including being the victim of sexual and/or physical abuse 
during childhood, or growing up in families with parental drug and alcohol abuse (26). Once established, the 
predominant trajectory is long-term dependence, with abstinence rates of 30% or lower after 10 years of 
observation and remaining stable thereafter with no ‘maturing out’ effect (27, 28).  
Consideration of an opiate-using ‘career’ is helpful (29, 30), but there is not one single trajectory and early 
quitters do exist (27, 31). Potential turning points occur where the trajectory is deflected towards 
abstinence, and entry into treatment is one of the most significant (26). However, cohort studies of opiate 
dependent individuals report 6-10 years of opioid use prior to treatment entry (27), and by then users have 
typically developed dependence and a range of serious, life-threatening drug-related problems. The illicit 
nature of heroin use means that it is strongly associated with crime and imprisonment, and the social stigma 
of use leads to low self-esteem, difficulty in finding work and loss of contact and support from family and 
friends. Users of both illicit and prescribed opiates perform poorly in tests of attention, executive function 
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and information processing when compared to healthy control subjects (32, 33). Added together, these 
factors mean that episodes of psychosocial treatment may be unsuccessful and relapse rates are high. It is 
extremely unlikely that a single treatment episode will result in abstinent recovery. 
 
Specific issues with psychosocial intervention research in OST populations 
A major problem with the evidence base is that the control intervention used in OST studies routinely 
includes counselling sessions in addition to methadone, leading Amato and colleagues to conclude that their 
review ‘did not evaluate the question of whether any ancillary psychosocial intervention is needed when 
methadone maintenance is provided, but the narrower question of whether a specific more structured 
intervention provides any additional benefit to a standard psychosocial support’ (21). In contrast, large 
outcome studies of OST services have concluded that agencies with more and better psychosocial 
interventions have better outcomes (34-36). A study of six methadone programmes in the USA found those 
providing more treatment services were associated with less heroin and cocaine use, less injecting, and less 
criminal behaviour among their patients (34). The most successful services provided regular counselling of 
good quality, achieved a high rate of attendance through a long-term maintenance and rehabilitation policy, 
and viewed counselling as the most important part of the rehabilitative process. Other large cohort studies 
have produced similar findings (35, 36). 
Therefore, the concept of ‘psychosocial intervention’ includes more than just a psychologically-driven 
treatment. A key RCT also pointed to a dose-response relationship for ‘dose’ of psychosocial support over 
the 6-month experimental period: the more treatment received the better the outcome (37). Opioid users 
entering treatment were maintained on a steady dose of 60-90mg methadone and randomised to one of 
three counselling conditions. The low-intensity group received methadone only (with minimal counsellor 
contact), the medium-intensity group methadone plus standard counselling (one session per week, adjusted 
according to weekly urinalysis results), and the high-intensity group methadone plus standard counselling 
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enhanced by other clinical services (sessions with a psychiatrist, employment counsellor, family therapist). 
The study showed that psychosocial interventions can improve the outcome of methadone treatment, but 
that a subset of patients in all study conditions performed well. At 12 months, the total cost per abstinent 
participant was lowest for the medium-intensity group. Therefore, it was possible to conclude that high 
levels of psychosocial support are not cost effective for all opiate dependent patients (38, 39). Some do well 
with methadone plus psychosocial intervention, as received by the intermediate-level treatment group, 
some need more intensive care, and others function well with methadone alone and little or no psychosocial 
support. 
There are further problems in defining the most appropriate outcome measure for psychosocial components 
of OST, with retention in treatment and abstinence from the primary problem drug most commonly 
reported (21). If opiate dependence is conceptualised as a chronic health problem such as hypertension, it 
might be expected that the consequences of the disorder will be prevented as long as the patient takes the 
medication, but will recur when the medication is stopped (14). It is therefore not clear where the ancillary 
psychosocial intervention fits into this model, and whether reduction in opiate use is a suitable outcome 
measure for judging its effectiveness. Secondary outcomes are less often reported in a comparable way, and 
include compliance (i.e. number of psychosocial sessions attended), craving, psychiatric 
symptoms/psychological distress, quality of life, severity of dependence, and death (21).  
Another complicating factor in interpreting the evidence is the dose of intervention received. Treatment of 
people with complex needs is associated with a high rate of dropout, and up to 50% of new admissions may 
exit against clinical advice (40). In Dutra’s analysis of psychosocial therapies for any illicit substance, one-
third dropped out of treatment groups before trial completion. The evidence suggests that rates are even 
higher in OST populations (41), with mean attendance rates in systematic reviews ranging between 23% and 
68%, despite optimal treatment conditions (21). 
 
8 
 
Issues with training and supervision 
In common with healthcare systems around the world, the global economic slowdown has impacted on 
healthcare provision in England. The Government’s policy of austerity has reduced the availability of 
treatment services for addiction, with 40% cuts in treatment budgets in some areas (42). Non-medical 
staffing accounts for about 50% of the treatment budget, and the largest group of staff are the ‘drug 
workers’, a group made up of clinicians from a range of backgrounds. The role of the drug worker is not 
always clear, and staff perform a number of administrative, therapeutic and case management roles (34, 43, 
44) in addition to taking primary responsibility for the delivery of the psychosocial component of treatment. 
As budgets are cut and caseloads rise, clinicians face an increasing administrative burden, including the 
requirement to complete treatment outcome measures, complete care plans, formally assess risk and attend 
to child safeguarding issues.  
It has proved very hard to train clinicians to deliver formal psychosocial interventions in practice. Staff are 
unclear on their role (43), and have little time, training or supervision in many services. The gap between 
research knowledge and clinical practice has been described as ‘both persistent and formidable’ (45), 
meaning that ‘the majority of treatment programs in the United States remain grounded in traditional 
counseling models that have largely not been evaluated rigorously’ (45). The quality of clinician training is 
variable, and rates of clinician turnover are high. Establishing the efficacy of a treatment approach in a 
clinical trial rarely ensures that it is used in routine practice. 
A review of four decades of addiction treatment outcome research led Miller and Moyers to conclude that 
substantial differences among therapists in client outcomes are common, and relational factors such as 
therapist empathy and therapeutic alliance can be significant determinants of addiction treatment outcome 
(46). This is equally true for therapists in OST services, where both therapist characteristics and technique 
are associated with a better outcome, but better therapist characteristics more so than technique (47). 
Therapists have often been incorporated in statistical analysis as if they were a fixed form of treatment, and 
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should be treated as if they were a random selection from the population of therapists that practice that 
therapy (48).  
 
The importance of organisational factors 
In addition to patient characteristics and staff competencies, measures of organisational functioning are also 
associated with treatment outcomes. The large DATOS study reported one year retention rates between 10 
different OST programs ranging between 15% and 76%. Although the services with the lowest retention 
rates treated clients with the most difficult problems (more alcohol and cocaine dependence, more 
psychological problems), the broad set of client attributes examined was not sufficient to explain the 
observed variations in retention rates (49). Organisational culture, including overall mission and the 
importance afforded to training and staff development, has been shown to be associated with treatment 
outcomes in the UK and beyond (50, 51). However, such organizational culture is damaged by frequent re-
tendering of clinical services, which has been identified as a potential threat to the quality of drug treatment 
in the UK (25). 
 
 
Four Ways to Move Forward 
There is a broad acceptance that psychosocial interventions are needed within OST, but research evidence 
doesn’t tell us how they should be delivered, to whom, and with what goal in mind. We suggest four possible 
ways forward? 
1. Stop packaging psychosocial interventions into ‘branded’ products 
Research in populations receiving OST falls foul of many of the criticisms previously levelled at ‘packaged’ 
psychosocial interventions (52). Here is another example of the equivalence paradox in psychotherapy 
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research, whereby active interventions are better than no intervention but no one treatment prevails. 
Relationship is neglected in favour of technique, and psychosocial treatment is seen ‘like a medication, as a 
piece of technology that requires only therapist skill and efficiency and patient compliance in order to be 
delivered’ (52).  
However, despite equivocal findings for ‘brand-name’ treatments, specific behavioural treatment 
components and practitioner competencies have been linked to more favourable outcomes in both alcohol 
and smoking cessation research (53, 54). Moos has outlined the common elements of effective treatments, 
and shown that these are similar in both natural recovery (55) professionally- or peer-led recovery (56). 
Therefore it may be helpful in both research and clinical practice in OST to create a typology of the 
techniques that are effective, and build treatment strategies from the bottom upwards.  
2. Focus on staff skills to deliver psychosocial interventions 
“The concern about costs and the recent cutbacks in funding for addiction treatment have worsened the 
paradox that has long existed in the field of addiction treatment. Although the patients suffer from the most 
complex combinations of medical, psychiatric and social problems, the modal therapist is a counsellor with 
very little formal training and often a distrust for scientifically based treatments” (39) 
This quote from O’Brien was published nearly 20 years ago, but can anything be said to have changed in that 
time? The UK has seen work on developing packages of care for use in OST services (57), and on developing 
core competencies for staff in delivering them (58). The recent focus on the importance of a clinician’s ability 
to form a therapeutic alliance (46) suggests that this should be the priority in treatment services before 
introducing technical aspects of treatment. By breaking down the treatment process into smaller units, it 
should be possible to train staff ‘from the bottom up’, equipping them with simple skills and ensuring that 
they are supervised adequately to deliver them. 
3. Research treatment systems, not individual interventions  
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An evidence base built on the RCT encourages manualised interventions that don’t translate easily to routine 
clinical practice. Evaluating the treatment system as a whole is an alternative approach, specifying minimum 
basic standards and then evaluating the addition or removal of individual components. Models to 
understand the ‘black box’ of treatment have been articulated (59), and have the advantage of setting up 
testable hypotheses about the effectiveness of components applied at different stages in the treatment 
journey. The pharmacological and psychosocial components of care have different objectives (reducing drug-
related harm and providing stabilisation versus tackling the underlying causes of addiction and developing 
the skills to overcome them), and greater sophistication is required to understand their roles and 
interactions. For example, there is good reason to believe that levels of motivation for change may differ at 
different stages of a treatment career, and there has been relatively little focus on what works to help a 
client move from stable maintenance on OST to total abstinence. This is particularly relevant in the UK, 
where there has been a political focus on people being ‘parked’ on methadone, implying that insufficient is 
being done to help people move on with their lives (25). 
Considering treatment systems also allows an examination of ‘stepped care’, whereby the intensity of 
intervention is titrated to the needs of the individual at a particular point in time. RCTs have shown that 
enhanced services produce better results, but that some patients have difficulty taking advantage of them. 
There appears to be a minimum level of psychosocial therapy that is necessary within any OST programme. 
More intensive therapy improves the clinical outcome, but only when matched to assessed need and even 
then reaching a ceiling effect (60). Evaluating an entire treatment system would increase scale, but also 
allow the removal of the artificial conceptual split between medication and psychosocial elements of 
treatment. For example, Brooner and colleagues have combined the principles of contingency management 
with OST medication to enhance engagement with psychosocial interventions (61-63). Finally, a systems 
approach might allow more consideration of what helps ensure that effective interventions are delivered in 
real world situations. The issue of technology transfer has been under-researched in the addictions field 
(64). 
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4. A treatment system includes both professional and peer-led elements 
OST services in the UK have been accused of lacking ambition for their patients, and a greater emphasis has 
been placed on ‘exiting treatment drug free’ as a main treatment outcome since 2010 (65). Although this has 
led to an unhelpful debate about the merits of harm reduction and abstinence, it has also developed the 
idea of a ‘recovery community’ and its potential role in helping people stop using opiates (66, 67). There has 
been a move to shift addiction treatment from an acute care model of biopsychosocial stabilization to a 
model of sustained recovery management, nesting this within larger recovery-orientated systems of care 
(68, 69). Evidence-based guidelines have emphasised the benefits of mutual self-help (23), but there is 
insufficient research to support Narcotics Anonymous attendance in helping people to move from OST to 
abstinent recovery (70). OST and 12-step programmes have been considered incompatible (71), as some 
consider the use of any medication to treat addiction as the antithesis of the first step i.e. ‘a continued effort 
at control rather than surrender’’ (72). The level of acceptance of OST patients within 12-Step groups in 
England is unknown, and in particular whether restrictions on them are the same as those described in the 
USA (e.g. the right to claim ‘‘clean time’’, speak at meetings, sponsor others or hold service positions) (72, 
73). 
In cost-cutting times, the emergence of recovery coaches and mentors that may fill the gap between 
professionally-delivered psychosocial interventions and mutual self-help is interesting, but has little 
supporting evidence yet. New recovery support institutions are rising within the space that has existed 
between professionally directed addiction treatment services and peer-based mutual-aid societies. These 
have not yet been fully evaluated in the scientific literature (74, 75), and evaluating whole ‘recovery-
orientated integrated systems of care’ would be one way of doing this. 
 
Conclusion 
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The evidence base for psychosocial interventions in OST services can be interpreted both positively and 
negatively, and the implications are significant for the cost of treatment provision. It may be wrong to think 
we can amass enough evidence to completely understand a complex issue such as opiate dependence, with 
its mix of biological, psychological and social underpinnings. However, when faced with equivocal evidence it 
is important to find a sensible way through that doesn’t adopt one of the polar extremes of psychosocial 
interventions for everyone or no one. Perhaps now is the time to be honest about the limitations of our 
knowledge, and persuade the funders of treatment services that both medication and psychosocial 
treatment are useful but the skill lies in blending them both into an effective treatment system rather than 
choosing one or the other. 
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